Navigation Links
Landmark Findings From ECLIPSE Program Show Improved Control of,Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery

ration of action, and accumulates over time in the body, it is rarely used to control BP during surgery, and is only used occasionally after surgery.

About Cleviprex

Cleviprex is a novel, investigational drug rationally designed to meet the needs of the acute care practitioner for an intravenous hypertensive agent. It is the first third-generation dihydropyridine calcium channel blocker that acts rapidly and reliably, is vascular- and arterial- selective, and has an ultrashort half-life. Cleviprex recently completed Phase III clinical trials.

MDCO-G

About The Medicines Company

The Medicines Company is committed to delivering innovative, cost- effective acute care products in the worldwide hospital marketplace. The Company markets Angiomax(R) (bivalirudin) in the U.S. and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Company also has two products in late-stage development, Cleviprex(TM) (clevidipine) and cangrelor. The Company's website is http://www.themedicinescompany.com.

Statements contained in this press release about The Medicines Company and Cleviprex that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
10. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
11. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
Post Your Comments:
(Date:10/22/2014)... NORWALK, Conn. , Oct. 22, 2014  Recently ... (GERD) have bolstered the already substantial database of evidence. ... and adoption of Stretta therapy for sufferers ... of clinical evidence supporting Stretta therapy as ... coverage policies that make Stretta therapy available to nearly ...
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... Valeritas, Inc., a leader in simple, disposable ... 2 diabetes, announced today that it has received a ... was presented October 16 th at Cardinal,s annual ... . The Cardinal Health Supply Chain ... metrics specifically targeted at the importance of developing collaborative ...
Breaking Medicine Technology:Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... , MAPLE GROVE, Minn., Dec. 3 Upsher-Smith ... plan for central nervous system (CNS) diseases with USL255 (extended ... epilepsy. USL255 is being developed with Upsher-Smith,s proprietary formulation technology ... 2010 for the adjunctive treatment of epilepsy patients with partial ...
... , HARRISBURG, Pa., Dec. 3 ... processing company build a new cold storage facility and ... at least 20 jobs, Governor Edward G. Rendell announced ... more than $2.9 million for three projects. The investments, ...
Cached Medicine Technology:Upsher-Smith Announces Milestone in Development of CNS Strategy 2Governor Rendell: New State Investments Bear Fruit in Adams County; Help Pharmaceutical Company Expand in Philadelphia 2
(Date:10/22/2014)... Texas (PRWEB) October 22, 2014 ... of completing their continuing education at home or ... have access to 20 brand new, premium Seminar-on-Demand ... robust catalog of over 2,000 hours ... fully customize their educational experience. With such a ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay ... (IVF) -- the incubation of embryos in a laboratory dish ... vagina, new research suggests. Scientists from the United States ... sharply cut costs for pricey IVF procedures among certain women. ... who don,t live near big-city assisted reproduction centers, the researchers ...
(Date:10/20/2014)... Florida (PRWEB) October 20, 2014 With ... former Gov. Charlie Crist made a brief fundraising stop ... Orlando on Thursday. , Fresh from a debate last ... to take the stage for the first seven minutes ... the former governor described the incident in one word: ...
(Date:10/20/2014)... October 20, 2014 T.E.N., a ... firm, announced today that William H. Murray, renowned ... 2014 ISE® Luminary Leadership Award winner. Presented annually, ... of an outstanding leader and industry practitioner for ... in advancing the information security industry. , Formerly ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... Professional Products, Inc.,(PPI) has been commissioned to ... with a Clinical Skills and Simulation Center called,the ... eighth floor of the,outpatient center building and is ... allows future doctors the chance to practice and,hone ...
... Inc. (Nasdaq: GTIV ), the nation,s leading ... today that it is,scheduled to present from 3:25 ... 2008,at the 29th Annual Raymond James Institutional Investors ... available to the public via a live audio ...
... PPD, Inc. (Nasdaq:,PPDI) today announced that its board ... of 2008 under its annual cash dividend policy. The,quarterly ... date for the,first quarter dividend is March 14, 2008, ... cash dividend policy and the payment of future quarterly,cash ...
... NEW YORK, Feb. 22 The Physicians Coalition,for ... clarity on,the safety of Botox(R) injections after reports ... indications., "Consumers who have had Botox(R) injections ... cosmetic indications should not be alarmed,by recent reports ...
... Medical,Inc., the global leader in devices for clot ... from the use of its Merci Retrieval,System(TM) were ... International Stroke Conference held in New Orleans, Louisiana,February ... the use,of the Merci Retrieval System in patients ...
... Enable an Internationally Interoperable Healthcare Identity Management ... ... Liberty Alliance, the global,identity consortium working to build a ... the launch of a,global public forum formed to develop an ...
Cached Medicine News:Health News:Professional Products, Inc. Integrates Clinical Skills and Simulation Center at the Johns Hopkins Hospital 2Health News:Gentiva(R) Health Services to Present March 3rd at Raymond James' 29th Annual Institutional Investors Conference in Orlando 2Health News:Gentiva(R) Health Services to Present March 3rd at Raymond James' 29th Annual Institutional Investors Conference in Orlando 3Health News:PPD Declares First Quarter Dividend 2Health News:Clarity for Consumers on Botox Complication and Death Reports 2Health News:Clarity for Consumers on Botox Complication and Death Reports 3Health News:Clarity for Consumers on Botox Complication and Death Reports 4Health News:2008 International Stroke Conference Highlights Impact of Merci Retrieval System 2Health News:Global Interoperability and Patient Privacy Focus of New Liberty Alliance Health Identity Management Group 2
Full Handle Laseredge Implant Blade Knife, 5.2 mm round tip. Blade dimension: 16.5 mm x 5.2 mm x 3.8 mm x 2.4 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 11.1 mm x 1.5 mm x 5.7 mm....
Medicine Products: